RT Journal Article
SR Electronic
T1 The association between the gut microbiome and 24-hour blood pressure measurements in the SCAPIS study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.08.23299598
DO 10.1101/2023.12.08.23299598
A1 Lin, Yi-Ting
A1 Sayols-Baixeras, Sergi
A1 Baldanzi, Gabriel
A1 Dekkers, Koen F.
A1 Hammar, Ulf
A1 Nguyen, Diem
A1 Nielsen, Nynne
A1 Eklund, Aron C.
A1 Varotsis, Georgios
A1 Holm, Jacob B.
A1 Nielsen, H. Bjørn
A1 Lind, Lars
A1 Bergström, Göran
A1 Smith, J. Gustav
A1 Engström, Gunnar
A1 Ärnlöv, Johan
A1 Sundström, Johan
A1 Orho-Melander, Marju
A1 Fall, Tove
YR 2023
UL http://medrxiv.org/content/early/2023/12/09/2023.12.08.23299598.abstract
AB Background and Aims Large population-based studies on gut microbiota and hypertension have been conducted using methods with low taxonomic resolution and office blood pressure. This study aims to investigate the relationship between specific characteristics of the gut microbiome and 24-hour blood pressure measurements.Methods and results The association of gut microbial species, determined by shotgun metagenomic sequencing of fecal samples, with 24-hour ambulatory blood pressure measurements was assessed in 4063 participants without antihypertensive medication from the Swedish CArdioPulmonary bioImage Study. Multivariable-adjusted models identified 140 microbial species associated with at least one of the 24-hour blood pressure traits. Notably, Roseburia faecis, R. inulinivorans, and Dorea longicatena were strongly positively associated with mean systolic and diastolic blood pressure, while Alistipes communis and A. shahii were inversely associated with diastolic blood pressure. An enrichment of threonine degradation I, Bifidobacterium shunt, and lactate production was observed in species associated with mean systolic and diastolic blood pressure. Species positively associated with blood pressure were in general also positively associated with secondary bile acids but negatively associated with primary bile acids and vitamin A-related metabolites.Conclusions In this large cross-sectional analysis, we identified a group of gut microbial species and microbial functions associated with blood pressure. Our findings provide insights into the relation of the gut microbiome and blood pressure, which can lead to a new understanding of the etiology of hypertension.Competing Interest StatementThe authors declare the following competing interests: N.N., A.C.E. and J.B.H., and H.B.N. are employees of Clinical Microbiomics. The funders had no role in study design, data collection and analysis, decision to publish, nor preparation of the manuscript. J.Ä. has received lecture fees from Novartis and AstraZeneca, and served on advisory boards for AstraZeneca and Boerhinger Ingelheim, all unrelated to the present paper. J.S. reports stock ownership in Anagram kommunikation AB and Symptoms Europe AB, unrelated to the present study. All other authors report no conflicts of interest in connection with this study.Funding StatementWe acknowledge the financial support from the European Research Council [ERC-STG-2018-801965 (T.F.); ERC-CoG-2014-649021 (M.O-M.), ERC-STG-2015-679242 (J.G.S.)], the Swedish Research Council [VR 2019-01471 (T.F.); 2018-02784 (M.O-M.); 2018-02837 (M.O-M.); 2021-03291 (M.O-M.); EXODIAB 2009-1039 (M.O-M.); 2019-01015 (J.Ä.); 2020-00243 (J.Ä.); 2019-01236 (G.E.); 2021-02273 (J.G.S.)], the Swedish Heart-Lung Foundation [HjÄrt-Lungfonden, 20190505 (T.F.); 20200711 (M.O-M.); 20180343, 20210357 (J.Ä.); 20200173 (G.E.); 20190526 (J.G.S.)], the A.L.F. governmental grant [2018-0148 (M.O-M.)], the Novo Nordic Foundation [NNF20OC0063886 (M.O-M.)], the Swedish Diabetes foundation [DIA 2018-375 (M.O-M.)], the Swedish Foundation for Strategic Research [LUDC-IRC 15-0067 (M.O-M.)], Göran Gustafsson foundation [2016 (T.F.)]; and Axel and Signe Lagerman's foundation (T.F.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the Declaration of Helsinki. The Swedish Ethical Review Authority approved the Swedish CardioPulmonary bioImage Study (DNR 2010-228-31M) and the present study (DNR 2018-315).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDe-identified de-hosted metagenomic sequencing data for SCAPIS samples can be accessed from the European Nucleotide Archive under accession number PRJEB51353 (https://www.ebi.ac.uk/ena/browser/view/prjeb51353). Access to pseudonymized SCAPIS phenotype data requires ethical approval from the Swedish Ethical Review Board and approval from the SCAPIS Data access board (https://www.scapis.org/data-access/). The source code and the summary data underlying all figures used to generate the results for the analysis are available at https://github.com/MolEpicUU/24hBP-mgs. https://github.com/MolEpicUU/24hBP-mgs